Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115570 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
NCT00115570: Completed Phase 3 study, sponsored by Sanofi.
NCT00115570 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 572 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115570, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Interventions
- DRUG insulin glargine
- DRUG Insulin glulisine
- DRUG insulin lispro
- DRUG NPH insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00115570 record still lists
NCT00115570 is an interventional study that assigns participants to a tested intervention. The registered 572 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 4 interventions - of which insulin glargine is the first listed.
NCT00115570 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00115570 about?
NCT00115570 is a clinical study titled "Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents". The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
What is the current status of trial NCT00115570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2005-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00115570?
The interventions under investigation include: insulin glargine (DRUG), Insulin glulisine (DRUG), insulin lispro (DRUG), NPH insulin (DRUG).
Who is sponsoring clinical trial NCT00115570?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00115570's enrollment target sits among peer trials
572 663rd of 2000 higher than 1,336 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- NCT07192055 · 572 participants · NA
Self-sampling to Optimize Anal Lesion Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia